Trial Profile
Real Life long term outcome data of Tocilizumab from a Swiss Center in Patients with Giant Cell Arteritis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jul 2018
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Giant cell arteritis
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2018 New trial record
- 16 Jun 2018 Long-term outcome results with Giant cell Arteritis were presented at the 19th Annual Congress of the European League Against Rheumatism.